Articles tagged with 'Vascular Intervention' | BIOTRONIK

BÜLACH, Switzerland – BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferior...

Five-year-data from the BIOSTEMI trial confirmed the superiority of BIOTRONIK’s Orsiro® drug-eluting stent (DES) over Xience DES in patients with acute ST-segment elevation myocardial infarction (STEMI). Dr. Juan F. Iglesias, Geneva University Hospit...

 BIOTRONIK is proud to announce the enrollment of the first patient in the BIONETIC-I study of the safety and efficacy of the Dynetic®-35 cobalt chromium balloon-expandable stent system for the treatment of atherosclerotic peripheral artery disease l...

BIOTRONIK is proud to announce the completion of enrollment of the investigator-initiated BIOPACT randomized controlled trial (RCT). This non-inferiority study evaluates the safety and efficacy of paclitaxel drug-coated balloons (DCBs), comparing the...

BIOTRONIK is pleased to announce the expansion of the Fortress® reinforced introducer sheath line, which is now available in 7- and 8F-compatible sizes in the United States and countries that recognize European CE Mark approval.  The Fortress introdu...

BIOTRONIK’s ultrathin-strut stent, Orsiro®*, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.1The latest results were presented by Prof. Thomas Pilgrim, In...